Catheter PrecisionVTAK
VTAK
About: Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System) which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.
Employees: 14
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
245% more capital invested
Capital invested by funds: $62.8K [Q3] → $217K (+$154K) [Q4]
0.24% more ownership
Funds ownership: 5.75% [Q3] → 6.0% (+0.24%) [Q4]
27% less funds holding
Funds holding: 11 [Q3] → 8 (-3) [Q4]
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
We haven’t received any recent analyst ratings for VTAK.
Financial journalist opinion
Neutral
GlobeNewsWire
1 month ago
Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
BRIDGEWATER, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its engagement with PCG Advisory, a leading investor relations, strategic communications, and digital strategies firm, to enhance investor outreach and communication efforts.
Neutral
MCAP MediaWire
1 month ago
Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
BRIDGEWATER, NJ, February 10, 2025 – PRISM MediaWire – Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a U.S.
Neutral
GlobeNewsWire
1 month ago
Catheter Precision to Attend and Participate in the 13th Internation Symposium on Left Atrial Appendage
FORT MILL, S.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 13th International Symposium on Left Atrial Appendage (ISLAA). ISLAA will take place on February 7th and 8th, 2025 in Austin, Texas.
Neutral
GlobeNewsWire
1 month ago
Catheter Precision, Inc. Announces The Closing of its Acquisition of PeriKard, LLC
FORT MILL, S.C., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announces that it has closed the previously announced acquisition of PeriKard, LLC.
Neutral
Accesswire
1 month ago
Catheter Precision to Attend the 30th International Atrial Fibrillation Symposium
FORT MILL, SOUTH CAROLINA / ACCESS Newswire / January 16, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 30th International Atrial Fibrillation Symposium in from January 16 - 18, 2025 in Boston, Massachusetts. The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation.
Neutral
Accesswire
1 month ago
Catheter Precision, Inc. Announces Definitive Agreement to Acquire PeriKard, LLC
FORT MILL, SC / ACCESSWIRE / January 15, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has entered into a definitive agreement to acquire PeriKard, LLC., in a transaction involving the issuance of restricted VTAK common stock for 100% of the LLC interests in PeriKard.
Neutral
Accesswire
1 month ago
Catheter Precision, Inc. Announces Initial LockeT Purchase From the University of Tennessee Medical Center
FORT MILL, SC / ACCESSWIRE / January 13, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it has received its first purchase order for LockeT from the southeast region. As previously announced, the company has recently expanded its US sales and clinical team in preparation for the national product launch of LockeT.
Neutral
Accesswire
2 months ago
Catheter Precision, Inc. Announces New Chief Financial Officer
FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.
Neutral
Accesswire
3 months ago
Catheter Precision, Inc. Announces Initial LockeT Purchase From Montefiore Medical Center
FORT MILL, SC / ACCESSWIRE / November 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced it has received its first purchase order for LockeT from the New York City area. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the NYC region.
Neutral
Accesswire
3 months ago
Catheter Precision, Inc. Announces Third Quarter Update and Financial Results
FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024. Highlights of the third quarter include: Commercial Endeavors Marie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.
Charts implemented using Lightweight Charts™